Calliditas Therapeutics Valuation
Is CALTX undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Unter dem Marktwert
Deutlich unter dem Marktwert
Price-To-Sales gegen Gleichaltrige
Price-To-Sales gegen Industrie
PM vs. Fair Ratio
Analysten-Prognose
Share Price vs Fair Value
What is the Fair Price of CALTX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Unter dem Marktwert: CALTX (SEK108.3) wird unter unserer Schätzung des Fair Value (SEK1871.89) gehandelt.
Deutlich unter dem Marktwert: CALTX wird um mehr als 20 % unter dem Marktwert gehandelt.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CALTX?
Other financial metrics that can be useful for relative valuation.
| What is CALTX's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | kr6.08b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 5x |
| Enterprise Value/EBITDA | -16.4x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does CALTX's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 7.4x | ||
SECARE Swedencare | 4.3x | 11.6% | kr10.2b |
CAMX Camurus | 17.1x | 25.1% | kr29.4b |
CLBIO Corline Biomedical | 7.2x | 44.6% | kr255.7m |
ORX Orexo | 0.9x | 13.3% | kr568.4m |
CALTX Calliditas Therapeutics | 5x | 31.1% | kr6.1b |
Price-To-Sales gegen Gleichaltrige: CALTX ist ein guter Wert, wenn man sein Price-To-Sales Verhältnis (4.9x) mit dem Durchschnitt der anderen Unternehmen (7x) vergleicht.
Price to Earnings Ratio vs Industry
How does CALTX's PE Ratio compare vs other companies in the SE Pharmaceuticals Industry?
Price-To-Sales gegen Industrie: CALTX ist aufgrund seines Price-To-Sales Verhältnisses (4.9x) im Vergleich zum Swedish Pharmaceuticals Branchendurchschnitt (8.7x) ein guter Wert.
Price to Sales Ratio vs Fair Ratio
What is CALTX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 5x |
| Fair PS Ratio | 10.7x |
PM vs. Fair Ratio: CALTX ist ein guter Wert auf der Grundlage des Verhältnisses Price-To-Sales (4.9x) im Vergleich zum geschätzten fairen Verhältnis Price-To-Sales (10.1x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | kr113.20 | kr208.00 +83.7% | 21.4% | kr270.00 | kr161.00 | n/a | 4 |
| Mar ’25 | kr111.40 | kr200.25 +79.8% | 26.1% | kr270.00 | kr140.00 | n/a | 4 |
| Feb ’25 | kr112.20 | kr202.75 +80.7% | 27.5% | kr280.00 | kr140.00 | n/a | 4 |
| Jan ’25 | kr127.10 | kr217.20 +70.9% | 26.5% | kr280.00 | kr140.00 | n/a | 5 |
| Dec ’24 | kr92.50 | kr217.20 +134.8% | 26.5% | kr280.00 | kr140.00 | n/a | 5 |
| Nov ’24 | kr90.85 | kr236.80 +160.6% | 20.5% | kr295.00 | kr154.00 | n/a | 5 |
| Oct ’24 | kr97.50 | kr236.80 +142.9% | 20.5% | kr295.00 | kr154.00 | n/a | 5 |
| Sep ’24 | kr91.55 | kr237.40 +159.3% | 20.0% | kr295.00 | kr157.00 | n/a | 5 |
| Aug ’24 | kr103.70 | kr246.40 +137.6% | 23.0% | kr310.00 | kr157.00 | n/a | 5 |
| Jul ’24 | kr86.70 | kr246.40 +184.2% | 23.0% | kr310.00 | kr157.00 | n/a | 5 |
| Jun ’24 | kr93.45 | kr246.40 +163.7% | 23.0% | kr310.00 | kr157.00 | n/a | 5 |
| May ’24 | kr124.50 | kr259.80 +108.7% | 20.0% | kr315.00 | kr179.00 | n/a | 5 |
| Apr ’24 | kr125.30 | kr259.80 +107.3% | 20.0% | kr315.00 | kr179.00 | kr113.40 | 5 |
| Mar ’24 | kr101.30 | kr255.80 +152.5% | 23.7% | kr315.00 | kr149.00 | kr111.40 | 5 |
| Feb ’24 | kr97.60 | kr246.80 +152.9% | 26.2% | kr305.00 | kr149.00 | kr112.20 | 5 |
| Jan ’24 | kr92.45 | kr236.00 +155.3% | 28.8% | kr305.00 | kr149.00 | kr127.10 | 4 |
| Dec ’23 | kr95.90 | kr233.50 +143.5% | 28.1% | kr300.00 | kr149.00 | kr92.50 | 4 |
| Nov ’23 | kr81.45 | kr229.50 +181.8% | 30.9% | kr300.00 | kr133.00 | kr90.85 | 4 |
| Oct ’23 | kr84.70 | kr229.50 +171.0% | 30.9% | kr300.00 | kr133.00 | kr97.50 | 4 |
| Sep ’23 | kr85.30 | kr242.67 +184.5% | 32.0% | kr300.00 | kr133.00 | kr91.55 | 3 |
| Aug ’23 | kr100.60 | kr241.67 +140.2% | 32.7% | kr300.00 | kr130.00 | kr103.70 | 3 |
| Jul ’23 | kr96.30 | kr241.67 +151.0% | 32.7% | kr300.00 | kr130.00 | kr86.70 | 3 |
| Jun ’23 | kr84.35 | kr212.50 +151.9% | 38.8% | kr295.00 | kr130.00 | kr93.45 | 2 |
| May ’23 | kr74.85 | kr202.50 +170.5% | 40.7% | kr285.00 | kr120.00 | kr124.50 | 2 |
| Apr ’23 | kr93.00 | kr202.50 +117.7% | 40.7% | kr285.00 | kr120.00 | kr125.30 | 2 |
Analysten-Prognose: Das Kursziel liegt um mehr als 20% über dem aktuellen Aktienkurs, aber die Analysten liegen nicht in einem statistisch sicheren Bereich der Übereinstimmung.